Aptorum Group Limited (APM)

GB — Healthcare Sector
Peers: ERYP  SRZN  UNCY  ARMP  AMTI  FRTX  AIM  BCDA  IPHA  ADXN  CYAD  DYAI  CYTO  DRMA  CFRX  EFTR  ADTX  NRBO  REVB 

Automate Your Wheel Strategy on APM

With Tiblio's Option Bot, you can configure your own wheel strategy including APM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol APM
  • Rev/Share 0.0
  • Book/Share 2.4678
  • PB 0.2357
  • Debt/Equity 0.1492
  • CurrentRatio 1.1652
  • ROIC 0.0037

 

  • MktCap 7143757.0
  • FreeCF/Share -0.2879
  • PFCF -4.6471
  • PE 286.1373
  • Debt/Assets 0.1909
  • DivYield 0
  • ROE 0.0008

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Aptorum Group Limited (APM)

  • IPO Date 2018-12-18
  • Website https://www.aptorumgroup.com
  • Industry Biotechnology
  • CEO Mr. Chung Yuen Huen
  • Employees 1
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.